Transient Leukopenia Induced by Combination Therapy for Severe SARS-CoV-2 Pneumonia
  • Sierra Sullivan
    Internal Medicine Department, Texas Tech University Health Sciences Center, Lubbock, Texas, USA
  • Natnicha Leelaviwat
    Internal Medicine Department, Texas Tech University Health Sciences Center, Lubbock, Texas, USA
  • Jesus Davalos
    Internal Medicine Department, Texas Tech University Health Sciences Center, Lubbock, Texas, USA
  • Abbie Evans
    Internal Medicine Department, Texas Tech University Health Sciences Center, Lubbock, Texas, USA
  • Mahmoud Abdelnabi
    Internal Medicine Department, Texas Tech University Health Sciences Center, Lubbock, Texas, USA
  • Neha Mittal
    Internal Medicine Department, Texas Tech University Health Sciences Center, Lubbock, Texas, USA

Keywords

SAR-CoV-2 pneumonia, transient leukopenia, remdesivir, baricitinib, dexamethasone

Abstract

Treatment strategies for patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to be heavily researched and ever-changing. Recent data has suggested that combination therapy with dexamethasone, remdesivir and baricitinib could decrease the severity and length of illness in patients with severe SARS-CoV-2. However; the data regarding the safety and side effects related to this combination therapy are limited to case reports. The purpose of this case report is to highlight a potentially life-threatening side effect of one or all medications mentioned above.

VIEW THE ENTIRE ARTICLE

References

  • Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of Covid-19. N Engl J Med 2020;383:1813–1826.
  • Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. Baricitinib plus remdesivir for hospitalized adults with Covid-19. N Engl J Med 2021;384:795–807.
  • Tsuchiya K, Fujisawa T, Mochizuka Y, Takuma S, Oishi K, Endo Y, et al. Transient leukocytopenia following combination therapy for COVID-19. Respir Investig 2022;60:158–161.
  • Chakraborty C, Sharma AR, Bhattacharya M, Agoramoorthy G, Lee S-S. The drug repurposing for COVID-19 clinical trials provide very effective therapeutic combinations: lessons learned from major clinical studies. Front Pharmacol 2021;12:704205.
  • McCullough PA, Alexander PE, Armstrong R, Arvinte C, Bain AF, Bartlett RP, et al. Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19). Rev Cardiovasc Med 2020;21:517.
  • National Institutes of Health. COVID-19 Treatment Guidelines 2022. Available from: https://www.covid19treatmentguidelines.nih.gov/ (accessed 3 October 2022).
  • Newburger PE, Dale DC. Evaluation and management of patients with isolated neutropenia. Semin Hematol 2013;50:198–206.
  • Views: 559
    HTML downloads: 105
    PDF downloads: 311


    Published: 2022-10-25
    Issue: 2022: Vol 9 No 10 (view)


    How to cite:
    1.
    Sullivan S, Leelaviwat N, Davalos J, Evans A, Abdelnabi M, Mittal N. Transient Leukopenia Induced by Combination Therapy for Severe SARS-CoV-2 Pneumonia. EJCRIM 2022;9 doi:10.12890/2022_003636.

    Most read articles by the same author(s)